Number of drugs taken | Subdivided control data† | Multiple clinical departments | P-value | |
---|---|---|---|---|
Number of patients | less than 6 | 516 | 128 | |
6 or more | 128 | 244 | ||
Number of drugs taken | less than 6 | 3.0 ± 1.0 | 4.3 ± 0.8 | < 0.01*, a |
6 or more | 7.5 ± 1.7 | 8.7 ± 2.4 | < 0.01*, a | |
Number of drugs involved CYP3A4-related potential DDIs | less than 6 | 1.4 ± 1.0 | 2.1 ± 1.2 | < 0.01*, a |
6 or more | 3.5 ± 1.6 | 4.0 ± 1.7 | < 0.01*, a | |
Incidence of CYP3A4-related potential DDI due to two or more drugs | less than 6 | 43.2% | 71.1% | < 0.01*, b |
6 or more | 89.8% | 94.7% | 0.090b | |
Incidence of CYP3A4-related potential DDI due to three or more drugs | less than 6 | 13.6% | 35.2% | < 0.01*, b |
6 or more | 74.2% | 81.2% | 0.142b |